ING Groep NV increased its position in shares of Globus Medical Inc (NYSE:GMED) by 23.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 10,938 shares of the medical device company’s stock after buying an additional 2,095 shares during the period. ING Groep NV’s holdings in Globus Medical were worth $450,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Goldman Sachs Group Inc. raised its stake in Globus Medical by 26.2% during the second quarter. Goldman Sachs Group Inc. now owns 166,090 shares of the medical device company’s stock worth $5,505,000 after buying an additional 34,513 shares during the last quarter. Retirement Systems of Alabama increased its stake in Globus Medical by 45.6% in the third quarter. Retirement Systems of Alabama now owns 135,562 shares of the medical device company’s stock valued at $4,029,000 after purchasing an additional 42,481 shares in the last quarter. Rhumbline Advisers increased its stake in Globus Medical by 7.4% in the third quarter. Rhumbline Advisers now owns 154,127 shares of the medical device company’s stock valued at $4,581,000 after purchasing an additional 10,679 shares in the last quarter. Atlantic Trust Group LLC bought a new stake in Globus Medical in the third quarter valued at $1,110,000. Finally, Columbia Partners L L C Investment Management bought a new stake in Globus Medical in the third quarter valued at $2,962,000. 69.67% of the stock is owned by institutional investors and hedge funds.
In other news, CAO Steven Payne sold 3,076 shares of Globus Medical stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $39.30, for a total transaction of $120,886.80. Following the completion of the transaction, the chief accounting officer now directly owns 23,847 shares in the company, valued at $937,187.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David D. Davidar sold 55,383 shares of Globus Medical stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $40.66, for a total transaction of $2,251,872.78. Following the transaction, the director now owns 752,236 shares of the company’s stock, valued at $30,585,915.76. The disclosure for this sale can be found here. Insiders have sold 73,459 shares of company stock valued at $2,947,260 over the last quarter. Corporate insiders own 28.21% of the company’s stock.
Globus Medical Inc (NYSE GMED) opened at $48.22 on Friday. The stock has a market cap of $4,647.25, a PE ratio of 43.84, a PEG ratio of 2.82 and a beta of 0.48. Globus Medical Inc has a twelve month low of $26.95 and a twelve month high of $48.40.
WARNING: “ING Groep NV Has $450,000 Position in Globus Medical Inc (GMED)” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://stocknewstimes.com/2018/02/18/ing-groep-nv-has-450000-position-in-globus-medical-inc-gmed-2.html.
Globus Medical Company Profile
Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.
Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical Inc (NYSE:GMED).
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.